The Deal
Sunday, November 8, 
8:58 am

Dow ventures on with $9.5B Kuwait deal; BASF targets acquisitions

Posted on December 13, 2007 at 2:56 PM
Filed under: Corporate Strategy | Joint Ventures and Alliances
[ Share ]  [ E-mail ]  [ Leave a Comment ]
zpetro.png

Dow Chemical Inc. CEO Andrew Liveris has often refuted the idea that his company is (or should be) a buyout candidate. Instead, Dow has put together an unprecedented string of joint ventures that combine its downstream assets with access to the pricey hydrocarbons that are its raw materials.

Thursday Dow announced what looks like its biggest JV yet, its third such deal with Petrochemical Industries of Kuwait, a unit of Kuwait Petroleum. Dow contributed five of its global businesses, valued at $19 billion, in exchange for $9.5 billion and half the new company. The move links the Middle Eastern company's energy supply with Dow's market reach. The joint venture creates a company based in the U.S. that will manufacture and sell polyethylene and other chemicals used in products ranging from plastic bottles, compact disks and computers to agricultural compounds. Overall, companies say the joint venture will have $11 billion in sales at its inception. The deal structure is similar to the 2004 deal between the two companies that created MEGlobal, which manufactures and markets ethylene glycol.

Dow is so committed to its JV strategy that it even put out a white paper on the topic in September. Meanwhile, rival chemical giant BASF AG of Germany continues with its strategy of trying to move closer to end-user markets, as it did with its 2006 acquisition of catalysts company Englehard in the U.S., which brought it closer to the auto business. CEO Juergen Hambrecht told reporters Thursday the company can spend up to $14.7 billion on acquisitions. — Gerald Magpily

See Dealscape Dec. 4 post
Reuters article on BASF
See the Bloomberg article
Our pervious post on Dow’s JVs

Join Corporate Dealmaker's LinkedIn forum

Comments
Post a comment


Search


Search For

Corporate Dealmaker Video


Linklaters' Schmidt on Pfizer-Wyeth review

Linklaters' Schmidt says how regulators handled Pfizer Inc.'s acquisition of Wyeth is an outlier of how others merger reviews will be conducted.
Decade of The Deal


Movers & Shakers


Juergen Lasowski
Onyx Pharmaceuticals Inc.

Edward Swallow
Northrop Grumman Corp.

Owen Mahoney
Outspark

Alice Kim
FLO TV Inc.

Eric Hausler
Isle of Capri Casinos Inc.
Juergen Lasowski, Onyx Pharmaceuticals Inc.
Edward Swallow, Northrop Grumman Corp.
Owen Mahoney, Outspark
Alice Kim, FLO TV Inc.
Eric Hausler, Isle of Capri Casinos Inc.


COMPLETE MOVERS & SHAKERS ARCHIVES

The Magazine


MACDdec1cover.gifAnd the winners are...
Even in a period when things like toxic credit default swaps and noxious structured investment vehicles dominate the conversation in many parts of the deal community, people are still willing to take the time to recognize skill and achievement in the strategic transactions that help those companies adapt and grow.
View the complete issue


Last Issue
Archives
Suggest a topic
Purchase a reprint
Subscribe to The Deal


Monthly Archives


Syndicate

Contributors

footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.